Literature DB >> 19397941

Effects of obestatin on feeding and body weight after standard or cafeteria diet in the rat.

Luigi Brunetti1, Sheila Leone, Giustino Orlando, Lucia Recinella, Claudio Ferrante, Annalisa Chiavaroli, Chiara Di Nisio, Pierpaolo Di Michele, Michele Vacca.   

Abstract

Obestatin is a gastric derived 23 amino acid peptide, which has shown anorectic effects in a number of experimental paradigms after both peripheral and central administration. On the other hand, several researchers were not able to confirm these data. Since all previous experiments have been performed in animals fed a standard laboratory diet, we studied obestatin effects in male Wistar rats fed both a standard laboratory chow (STD) diet (3.5% fat, 63% carbohydrate, 14% protein, 19.5% other components without caloric value; 3.20 kcal/g) and a highly palatable cafeteria-style (CAF) diet (30% fat, 56% carbohydrate, 14% protein; 4.20 kcal/g). Vehicle or obestatin (10, 50 or 100 nmol/kg) was injected intraperitoneally daily for 12 days. In STD diet rats, obestatin decreased daily caloric intake and body weight gain compared to vehicle treated rats. The anorectic and weight reducing effects of obestatin treatment were evidenced since day 6 and day 8 of treatment, respectively, and were consistent through the end of treatment. On the other hand, in CAF diet rats, obestatin treatment did not modify either daily caloric intake or body weight gain. In CAF diet rats, the percentage intake from standard food was decreased, balanced by an increase in cafeteria food intake. Obestatin treatment affected neither water consumption nor the intake of any specific food within the cafeteria diet. In conclusion, obestatin decreases caloric intake and body weight gain, but only in rats fed a STD diet.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19397941     DOI: 10.1016/j.peptides.2009.04.011

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  8 in total

1.  Changes in feeding and drinking motivations and glucose content in male rats after single or chronic administration of obestatin or its fragment (1-4).

Authors:  E S Motorykina; E E Khirazova; M V Maslova; A S Maklakova; A V Graf; A A Bayzhymanov; O D Kurko; L A Zamyatina; L A Andreyeva; N A Sokolova; N F Myasoyedov; A A Kamenskii
Journal:  Dokl Biol Sci       Date:  2015-03-13

Review 2.  Neurochemical regulators of food behavior for pharmacological treatment of obesity: current status and future prospects.

Authors:  Gayane Sargis Vardanyan; Hasmik Samvel Harutyunyan; Michail Iosif Aghajanov; Ruben Sargis Vardanyan
Journal:  Future Med Chem       Date:  2020-10-12       Impact factor: 3.808

Review 3.  Interaction between gastric and upper small intestinal hormones in the regulation of hunger and satiety: ghrelin and cholecystokinin take the central stage.

Authors:  Andreas Stengel; Yvette Taché
Journal:  Curr Protein Pept Sci       Date:  2011-06       Impact factor: 3.272

Review 4.  Biological effects of obestatin.

Authors:  Jiang-Bo Li; Akihiro Asakawa; Kaichun Cheng; Yingxiao Li; Huhe Chaolu; Minglun Tsai; Akio Inui
Journal:  Endocrine       Date:  2011-03-20       Impact factor: 3.633

Review 5.  Ghrelin, des-acyl ghrelin and nesfatin-1 in gastric X/A-like cells: role as regulators of food intake and body weight.

Authors:  Andreas Stengel; Miriam Goebel; Lixin Wang; Yvette Taché
Journal:  Peptides       Date:  2009-11-26       Impact factor: 3.750

6.  Yin and Yang - the Gastric X/A-like Cell as Possible Dual Regulator of Food Intake.

Authors:  Andreas Stengel; Yvette Taché
Journal:  J Neurogastroenterol Motil       Date:  2012-04-09       Impact factor: 4.924

7.  Protective Effect of Cudrania tricuspidata Extract against High-Fat Diet Induced Nonalcoholic Fatty Liver Disease through Nrf-2/HO-1 Pathway.

Authors:  Jitendra Shrestha; Dong-Jae Baek; Yoon-Sin Oh; Sam-Seok Cho; Sung-Hwan Ki; Eun-Young Park
Journal:  Molecules       Date:  2021-04-22       Impact factor: 4.411

Review 8.  Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes.

Authors:  Elaine Cowan; Kerry J Burch; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2016-05-27       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.